Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $11.3 million.

  • BioLineRx's Non-Current Assets fell 2425.97% to $11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.3 million, marking a year-over-year decrease of 2425.97%. This contributed to the annual value of $11.8 million for FY2024, which is 2950.66% down from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Non-Current Assets is $11.3 million, which was down 2425.97% from $11.4 million recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Non-Current Assets peaked at $24.3 million during Q1 2023, and registered a low of $11.3 million during Q3 2025.
  • In the last 3 years, BioLineRx's Non-Current Assets had a median value of $15.5 million in 2024 and averaged $16.5 million.
  • Per our database at Business Quant, BioLineRx's Non-Current Assets plummeted by 3807.48% in 2024 and then tumbled by 2425.97% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Non-Current Assets stood at $16.7 million in 2023, then decreased by 29.51% to $11.8 million in 2024, then decreased by 4.42% to $11.3 million in 2025.
  • Its Non-Current Assets stands at $11.3 million for Q3 2025, versus $11.4 million for Q2 2025 and $11.6 million for Q1 2025.